Hubertina C. J. Scheepers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hubertina C. J. Scheepers has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Marc E. A. Spaanderman
Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, Maastricht University Medical Center+, Maastricht, the Netherlands; School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center+, Maastricht, the Netherlands
7 shared publications - Luc Smits
Maastricht University
6 shared publications - Carmen Dirksen
Department of Clinical Epidemiology and Medical Technology Assessment Maastricht University Medical Center+ Maastricht The Netherlands
5 shared publications - Linda Jacqueline Elisabeth Meertens
Department of Epidemiology, Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, The Netherlands
5 shared publications - Pim van Montfort
Department of Epidemiology, Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, The Netherlands
4 shared publications - Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 45 (1)
Placental angiogenic biomarkers for triage of suspected preeclampsia and prediction of maternal and neonatal morbidity in a high-risk population
- 12 November 2026
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 45 (1)
Open AccessPlacental angiogenic biomarkers for triage of suspected preeclampsia and prediction of maternal and neonatal morbidity in a high-risk population
- Open Access
- 10 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 633-645
Barriers and Facilitators for Bringing Model‐Informed Precision Dosing to the Patient's Bedside: A Systematic Review
Model‐informed precision dosing (MIPD) utilizes mathematical models to predict optimal medication doses for a specific patient or patient population. However, the factors influencing the implementation of MIPD have not been fully elucidated, hindering its widespread use in clinical practice. A systematic review was conducted in PubMed from inception to December 2022, aiming to identify barriers and facilitators for the implementation of MIPD into patient care. Articles with a focus on implementation of MIPD were eligible for this review. After screening titles and abstracts, full articles investigating the clinical implementation of MIPD were included for data extraction. Of 790 records identified, 15 publications were included. A total of 72 barriers and facilitators across seven categories were extracted through a hybrid thematic analysis. Barriers comprised limited data for model validation, unclear regulatory pathways for model endorsement and additional drug level measurements required for certain types of MIPD. Facilitators encompassed the development of user‐friendly MIPD tools continuously updated based on user feedback and data. Collaborative efforts among diverse stakeholders for model validation and implementation, along with education of end‐users, may promote the utilization of MIPD in patient care. Despite ongoing challenges, this systematic review revealed various strategies to facilitate the clinical implementation of MIPD.
- 10 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 633-645
Open AccessBarriers and Facilitators for Bringing Model‐Informed Precision Dosing to the Patient's Bedside: A Systematic Review
Model‐informed precision dosing (MIPD) utilizes mathematical models to predict optimal medication doses for a specific patient or patient population. However, the factors influencing the implementation of MIPD have not been fully elucidated, hindering its widespread use in clinical practice. A systematic review was conducted in PubMed from inception to December 2022, aiming to identify barriers and facilitators for the implementation of MIPD into patient care. Articles with a focus on implementation of MIPD were eligible for this review. After screening titles and abstracts, full articles investigating the clinical implementation of MIPD were included for data extraction. Of 790 records identified, 15 publications were included. A total of 72 barriers and facilitators across seven categories were extracted through a hybrid thematic analysis. Barriers comprised limited data for model validation, unclear regulatory pathways for model endorsement and additional drug level measurements required for certain types of MIPD. Facilitators encompassed the development of user‐friendly MIPD tools continuously updated based on user feedback and data. Collaborative efforts among diverse stakeholders for model validation and implementation, along with education of end‐users, may promote the utilization of MIPD in patient care. Despite ongoing challenges, this systematic review revealed various strategies to facilitate the clinical implementation of MIPD.
- Open Access
- 28 November 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 169 (1) , 399-407
Cost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth
To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial. We included women with a singleton pregnancy and a previous spontaneous preterm birth <37 weeks of gestation of a singleton. Women were randomized between aspirin 80 mg daily and placebo, initiated between 8 and 16 weeks of gestation. We estimated the difference in preterm births (<37 weeks of gestation), and maternal and neonatal healthcare costs using seemingly unrelated linear regression analyses. Bootstrapping was performed to estimate statistical uncertainty. A total of 387 women were included: 194 in the aspirin group and 193 in the placebo group. We observed a small, statistically non‐significant difference in preterm birth (21.2% vs. 25.4%; risk difference −4.3%; 95% CI: −12.7% to 4.1%) and healthcare costs (mean –€99; 95% CI: –€2385 to €2325) in the aspirin group compared to placebo. The cost‐effectiveness acceptability curve showed that the probability of aspirin being cost‐effective was 54% for a willingness to pay threshold of €0 for one prevented preterm birth and 78% for €50 000 for one prevented preterm birth. Our findings suggest that aspirin is the dominant strategy over placebo for the prevention of preterm birth. However, there was substantial uncertainty around the results and definite conclusions regarding the cost‐effectiveness of aspirin cannot be drawn.
- 28 November 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 169 (1) , 399-407
Open AccessCost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth
To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial. We included women with a singleton pregnancy and a previous spontaneous preterm birth <37 weeks of gestation of a singleton. Women were randomized between aspirin 80 mg daily and placebo, initiated between 8 and 16 weeks of gestation. We estimated the difference in preterm births (<37 weeks of gestation), and maternal and neonatal healthcare costs using seemingly unrelated linear regression analyses. Bootstrapping was performed to estimate statistical uncertainty. A total of 387 women were included: 194 in the aspirin group and 193 in the placebo group. We observed a small, statistically non‐significant difference in preterm birth (21.2% vs. 25.4%; risk difference −4.3%; 95% CI: −12.7% to 4.1%) and healthcare costs (mean –€99; 95% CI: –€2385 to €2325) in the aspirin group compared to placebo. The cost‐effectiveness acceptability curve showed that the probability of aspirin being cost‐effective was 54% for a willingness to pay threshold of €0 for one prevented preterm birth and 78% for €50 000 for one prevented preterm birth. Our findings suggest that aspirin is the dominant strategy over placebo for the prevention of preterm birth. However, there was substantial uncertainty around the results and definite conclusions regarding the cost‐effectiveness of aspirin cannot be drawn.
- Open Access
- 17 May 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (2) , 228.e1-228.e9
Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach
- 17 May 2024
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 232 (2) , 228.e1-228.e9
Open AccessOptimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach
- Open Access
- 10 May 2024
- Published by Taylor & Francis in Women's Reproductive Health
- Vol. 11 (4) , 852-875
How Do Partners Make Pregnancy-Related Decisions? Understanding the Decision-Making Process of Couples: A Scoping Review
- 10 May 2024
- Published by Taylor & Francis in Women's Reproductive Health
- Vol. 11 (4) , 852-875
Open AccessHow Do Partners Make Pregnancy-Related Decisions? Understanding the Decision-Making Process of Couples: A Scoping Review
- Open Access
A user-driven framework for dose selection in pregnancy: proof-of-concept for sertraline
Despite growing knowledge of pregnancy-induced changes in physiology that may alter maternal and fetal pharmacokinetics, and therefore drug efficacy and safety, evidence-based antenatal doses are lacking for most drugs. Pharmacokinetic models and expanding clinical data in pregnancy may support antenatal doses. In this article, we introduce a comprehensive and user-driven Framework for Dose Selection in Pregnancy (FDSP), developed and validated to support the clinical implementation of best-evidence and in some cases, model-informed doses for pregnant women and/or fetuses. After initial development and validation by experts, the framework prototype was piloted to formulate an antenatal dosing strategy for sertraline in depression and anxiety disorders. Next, the framework was validated and assessed for usability by a multidisciplinary working committee of end-users comprising healthcare practitioners, experts from other disciplines including pharmacometrics, reproductive toxicology and medical ethics, alongside pregnant women and a partner. The resulting framework encompasses the following: rationale for drug selection, a comprehensive analysis of pharmacokinetic and dose-related efficacy and safety data, and implementation aspects including feasibility and desirability of the recommended antenatal dose based on a structured maternal and fetal benefit-risk assessment. An antenatal dose recommendation for sertraline, as a proof-of-concept, was formulated using this approach and endorsed for clinical use by the working committee. The FDSP, as demonstrated by the example of sertraline, is fit for supporting the development of best-evidence acceptable and clinically feasible antenatal doses.
Open AccessA user-driven framework for dose selection in pregnancy: proof-of-concept for sertraline
Despite growing knowledge of pregnancy-induced changes in physiology that may alter maternal and fetal pharmacokinetics, and therefore drug efficacy and safety, evidence-based antenatal doses are lacking for most drugs. Pharmacokinetic models and expanding clinical data in pregnancy may support antenatal doses. In this article, we introduce a comprehensive and user-driven Framework for Dose Selection in Pregnancy (FDSP), developed and validated to support the clinical implementation of best-evidence and in some cases, model-informed doses for pregnant women and/or fetuses. After initial development and validation by experts, the framework prototype was piloted to formulate an antenatal dosing strategy for sertraline in depression and anxiety disorders. Next, the framework was validated and assessed for usability by a multidisciplinary working committee of end-users comprising healthcare practitioners, experts from other disciplines including pharmacometrics, reproductive toxicology and medical ethics, alongside pregnant women and a partner. The resulting framework encompasses the following: rationale for drug selection, a comprehensive analysis of pharmacokinetic and dose-related efficacy and safety data, and implementation aspects including feasibility and desirability of the recommended antenatal dose based on a structured maternal and fetal benefit-risk assessment. An antenatal dose recommendation for sertraline, as a proof-of-concept, was formulated using this approach and endorsed for clinical use by the working committee. The FDSP, as demonstrated by the example of sertraline, is fit for supporting the development of best-evidence acceptable and clinically feasible antenatal doses.
- Open Access
- 25 November 2020
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 20 (1) , 1-6
CCT: continuous care trial - a randomized controlled trial of the provision of continuous care during labor by maternity care assistants in the Netherlands
Background: In 2009, the Steering Committee for Pregnancy and Childbirth in the Netherlands recommended the implementation of continuous care during labor in order to improve perinatal outcomes. However, in current care, routine maternity caregivers are unable to provide this type of care, resulting in an implementation rate of less than 30%. Maternity care assistants (MCAs), who already play a nursing role in low risk births in the second stage of labor and in homecare during the postnatal period, might be able to fill this gap. In this study, we aim to explore the (cost) effectiveness of adding MCAs to routine first- and second-line maternity care, with the idea that these MCAs would offer continuous care to women during labor. Methods: A randomized controlled trial (RCT) will be performed comparing continuous care (CC) with care-as-usual (CAU). All women intending to have a vaginal birth, who have an understanding of the Dutch language and are > 18 years of age, will be eligible for inclusion. The intervention consists of the provision of continuous care by a trained MCA from the moment the supervising maternity caregiver establishes that labor has started. The primary outcome will be use of epidural analgesia (EA). Our secondary outcomes will be referrals from primary care to secondary care, caesarean delivery, instrumental delivery, adverse outcomes associated with epidural (fever, augmentation of labor, prolonged labor, postpartum hemorrhage, duration of postpartum stay in hospital for mother and/or newborn), women’s satisfaction with the birth experience, cost-effectiveness, and a budget impact analysis. Cost effectiveness will be calculated by QALY per prevented EA based on the utility index from the EQ-5D and the usage of healthcare services. A standardized sensitivity analysis will be carried out to quantify the outcome in addition to a budget impact analysis. In order to show a reduction from 25 to 17% in the primary outcome (alpha 0.05 and bèta 0.20), taking into account an extra 10% sample size for multi-level analysis and an attrition rate of 10%, 2 × 496 women will be needed (n = 992). Discussion: We expect that adding MCAs to the routine maternity care team will result in a decrease in the use of epidural analgesia and subsequent costs without a reduction in patient satisfaction. It will therefore be a cost-effective intervention. Trial registration: Trial Registration: Netherlands Trial Register, NL8065. Registered 3 October 2019 - Retrospectively registered.
- 25 November 2020
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 20 (1) , 1-6
Open AccessCCT: continuous care trial - a randomized controlled trial of the provision of continuous care during labor by maternity care assistants in the Netherlands
Background: In 2009, the Steering Committee for Pregnancy and Childbirth in the Netherlands recommended the implementation of continuous care during labor in order to improve perinatal outcomes. However, in current care, routine maternity caregivers are unable to provide this type of care, resulting in an implementation rate of less than 30%. Maternity care assistants (MCAs), who already play a nursing role in low risk births in the second stage of labor and in homecare during the postnatal period, might be able to fill this gap. In this study, we aim to explore the (cost) effectiveness of adding MCAs to routine first- and second-line maternity care, with the idea that these MCAs would offer continuous care to women during labor. Methods: A randomized controlled trial (RCT) will be performed comparing continuous care (CC) with care-as-usual (CAU). All women intending to have a vaginal birth, who have an understanding of the Dutch language and are > 18 years of age, will be eligible for inclusion. The intervention consists of the provision of continuous care by a trained MCA from the moment the supervising maternity caregiver establishes that labor has started. The primary outcome will be use of epidural analgesia (EA). Our secondary outcomes will be referrals from primary care to secondary care, caesarean delivery, instrumental delivery, adverse outcomes associated with epidural (fever, augmentation of labor, prolonged labor, postpartum hemorrhage, duration of postpartum stay in hospital for mother and/or newborn), women’s satisfaction with the birth experience, cost-effectiveness, and a budget impact analysis. Cost effectiveness will be calculated by QALY per prevented EA based on the utility index from the EQ-5D and the usage of healthcare services. A standardized sensitivity analysis will be carried out to quantify the outcome in addition to a budget impact analysis. In order to show a reduction from 25 to 17% in the primary outcome (alpha 0.05 and bèta 0.20), taking into account an extra 10% sample size for multi-level analysis and an attrition rate of 10%, 2 × 496 women will be needed (n = 992). Discussion: We expect that adding MCAs to the routine maternity care team will result in a decrease in the use of epidural analgesia and subsequent costs without a reduction in patient satisfaction. It will therefore be a cost-effective intervention. Trial registration: Trial Registration: Netherlands Trial Register, NL8065. Registered 3 October 2019 - Retrospectively registered.
- 1 November 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 254, 315-320
Ketonuria is not associated with hyperemesis gravidarum disease severity
- 1 November 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 254, 315-320
Ketonuria is not associated with hyperemesis gravidarum disease severity
- 1 February 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 245, 162-167
Determinants of disease course and severity in hyperemesis gravidarum
- 1 February 2020
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 245, 162-167
Determinants of disease course and severity in hyperemesis gravidarum
- Open Access
- 18 January 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (7) , 875-883
Low‐dose‐aspirin usage among women with an increased preeclampsia risk: A prospective cohort study
Introduction: Low‐dose aspirin (LDA) prophylaxis has been shown to reduce women’s preeclampsia risk. Evidence regarding LDA adherence rates of pregnant women is based almost exclusively on clinical trials, giving a potentially biased picture. Moreover, these studies do not report on determinants of adherence. Since 2017, obstetric healthcare professionals in a Dutch region have assessed women’s preeclampsia risk by means of a prediction tool and counseled those with an above‐population average risk on LDA as a prophylactic measure.Material and methods: From 2017 to 2018, 865 women were recruited in multiple centers and prospectively followed using web‐based surveys (Expect Study II). Rates and determinants of LDA usage among women with an increased preeclampsia risk in daily practice were assessed. Results were compared with findings in a similar cohort from a care‐as‐usual setting lacking risk‐based counseling (Expect Study I, n = 2614). Netherlands Trial Register NTR4143.Results: In total, 306 women had a predicted increased preeclampsia risk. LDA usage was higher for women receiving risk‐based care than care‐as‐usual (29.4% vs 1.5%, odds ratio 19.1, 95% confidence interval 11.2‐32.5). Daily LDA usage was positively correlated with both predicted risk and women’s concerns regarding preeclampsia. Most reported reasons for non‐ or incomplete use were unawareness of LDA as a preventive intervention, concerns about potential adverse effects and doubts regarding the benefits.Conclusions: Risk‐based counseling was associated with a higher prevalence of LDA usage, but general usage rates were low. Future research regarding potential factors improving the usage of LDA during pregnancy is necessary.
- 18 January 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (7) , 875-883
Open AccessLow‐dose‐aspirin usage among women with an increased preeclampsia risk: A prospective cohort study
Introduction: Low‐dose aspirin (LDA) prophylaxis has been shown to reduce women’s preeclampsia risk. Evidence regarding LDA adherence rates of pregnant women is based almost exclusively on clinical trials, giving a potentially biased picture. Moreover, these studies do not report on determinants of adherence. Since 2017, obstetric healthcare professionals in a Dutch region have assessed women’s preeclampsia risk by means of a prediction tool and counseled those with an above‐population average risk on LDA as a prophylactic measure.Material and methods: From 2017 to 2018, 865 women were recruited in multiple centers and prospectively followed using web‐based surveys (Expect Study II). Rates and determinants of LDA usage among women with an increased preeclampsia risk in daily practice were assessed. Results were compared with findings in a similar cohort from a care‐as‐usual setting lacking risk‐based counseling (Expect Study I, n = 2614). Netherlands Trial Register NTR4143.Results: In total, 306 women had a predicted increased preeclampsia risk. LDA usage was higher for women receiving risk‐based care than care‐as‐usual (29.4% vs 1.5%, odds ratio 19.1, 95% confidence interval 11.2‐32.5). Daily LDA usage was positively correlated with both predicted risk and women’s concerns regarding preeclampsia. Most reported reasons for non‐ or incomplete use were unawareness of LDA as a preventive intervention, concerns about potential adverse effects and doubts regarding the benefits.Conclusions: Risk‐based counseling was associated with a higher prevalence of LDA usage, but general usage rates were low. Future research regarding potential factors improving the usage of LDA during pregnancy is necessary.